Your browser doesn't support javascript.
loading
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats.
Miller, Ami; Carr, Stephen; Rabbitts, Terry; Ali, Hanif.
Afiliación
  • Miller A; Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, UK.
  • Carr S; Research Complex at Harwell, Rutherford Appleton Laboratory, Oxon, UK.
  • Rabbitts T; Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, UK.
  • Ali H; Quadrucept Bio Limited, Cambridge, UK.
MAbs ; 12(1): 1752529, 2020.
Article en En | MEDLINE | ID: mdl-32316838
ABSTRACT
The success of therapeutic antibodies is largely attributed for their exquisite specificity, homogeneity, and functionality. There is, however, a need to engineer antibodies to extend and enhance their potency. One parameter is functional affinity augmentation, since antibodies matured in vivo have a natural affinity threshold. Generation of multivalent antibodies is one option capable of surpassing this affinity threshold through increased avidity. In this study, we present a novel platform consisting of an array of multivalent antibody formats, termed Quads, generated using the self-assembling tetramerization domain from p53. We demonstrate the versatility of this tetramerization domain by engineering anti-tumor necrosis factor (TNF) Quads that exhibit major increases in binding potency and in neutralizing TNF-mediated cytotoxicity compared to parental anti-TNF molecules. Further, Quads are amenable to fusion with different binding domains, allowing generation of novel multivalent monospecific and bispecific formats. Quads are thus a novel group of molecules that can be engineered to yield potential therapeutics with novel modalities and potencies.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ingeniería de Proteínas / Anticuerpos Biespecíficos / Multimerización de Proteína / Anticuerpos Monoclonales / Afinidad de Anticuerpos Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ingeniería de Proteínas / Anticuerpos Biespecíficos / Multimerización de Proteína / Anticuerpos Monoclonales / Afinidad de Anticuerpos Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article